These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 22541730)

  • 1. [Anti-drug antibodies, auto-antibodies and biotherapy in psoriasis].
    Jullien D
    Ann Dermatol Venereol; 2012 Apr; 139 Suppl 2():S58-67. PubMed ID: 22541730
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Autoantibodies in psoriasis as predictors for loss of response and anti-infliximab antibody induction.
    Hoffmann JH; Hartmann M; Enk AH; Hadaschik EN
    Br J Dermatol; 2011 Dec; 165(6):1355-8. PubMed ID: 21801160
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The first decade of biologic TNF antagonists in clinical practice: lessons learned, unresolved issues and future directions.
    Sfikakis PP
    Curr Dir Autoimmun; 2010; 11():180-210. PubMed ID: 20173395
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of etanercept in psoriasis after switching from other treatments: an observational study.
    Mazzotta A; Esposito M; Costanzo A; Chimenti S
    Am J Clin Dermatol; 2009; 10(5):319-24. PubMed ID: 19658444
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prospective new biologic therapies for psoriasis and psoriatic arthritis.
    Mortel MR; Emer J
    J Drugs Dermatol; 2010 Aug; 9(8):947-58. PubMed ID: 20684145
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A follow-up study in 28 patients treated with infliximab for severe recalcitrant psoriasis: evidence for efficacy and high incidence of biological autoimmunity.
    Poulalhon N; Begon E; Lebbé C; Lioté F; Lahfa M; Bengoufa D; Morel P; Dubertret L; Bachelez H
    Br J Dermatol; 2007 Feb; 156(2):329-36. PubMed ID: 17223874
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunogenicity of biotherapy used in psoriasis: the science behind the scenes.
    Jullien D; Prinz JC; Nestle FO
    J Invest Dermatol; 2015 Jan; 135(1):31-38. PubMed ID: 25120005
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunogenicity of biologics used in the treatment of moderate to severe psoriasis.
    Patel V; Efimov A; Baker D; Kang AS
    Hum Antibodies; 2021; 29(3):171-178. PubMed ID: 34151782
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Interleukin 10 in disseminated lupus erythematosus].
    Emilie D
    J Soc Biol; 2002; 196(1):19-21. PubMed ID: 12134628
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Etanercept provides a more physiological approach in the treatment of psoriasis.
    Altomare G; Ayala F; Berardesca E; Chimenti S; Giannetti A; Girolomoni G; Lotti T; Martini P; Peserico A; Guerra AP; Vena GA
    Dermatol Ther; 2008 Oct; 21 Suppl 2():S1-14. PubMed ID: 18837727
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunogenicity of biotherapeutics-an overview.
    Subramanyam M
    J Immunotoxicol; 2006 Sep; 3(3):151-6. PubMed ID: 18958695
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Infliximab, but not etanercept, induces IgM anti-double-stranded DNA autoantibodies as main antinuclear reactivity: biologic and clinical implications in autoimmune arthritis.
    De Rycke L; Baeten D; Kruithof E; Van den Bosch F; Veys EM; De Keyser F
    Arthritis Rheum; 2005 Jul; 52(7):2192-201. PubMed ID: 15986349
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Infectious risk].
    Calabuig E; Salavert M
    Actas Dermosifiliogr; 2008 Jul; 99 Suppl 4():14-22. PubMed ID: 19080987
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inflammation in atherosclerosis and psoriasis: common pathogenic mechanisms and the potential for an integrated treatment approach.
    Späh F
    Br J Dermatol; 2008 Aug; 159 Suppl 2():10-7. PubMed ID: 18700910
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New biologics for psoriasis and psoriatic arthritis.
    Rozenblit M; Lebwohl M
    Dermatol Ther; 2009; 22(1):56-60. PubMed ID: 19222517
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Briakinumab.
    Lima XT; Abuabara K; Kimball AB; Lima HC
    Expert Opin Biol Ther; 2009 Aug; 9(8):1107-13. PubMed ID: 19569977
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of antinuclear autoantibodies in patients with psoriasis treated with anti-tumor necrosis factor-alpha agents: a retrospective long-term study.
    Saraceno R; Specchio F; Torres T; Nisticò SP; Rizza S; Chimenti S
    J Am Acad Dermatol; 2012 May; 66(5):e180-2. PubMed ID: 22507590
    [No Abstract]   [Full Text] [Related]  

  • 18. Low frequency of anticyclic citrullinated peptide antibodies in psoriatic arthritis but not in cutaneous psoriasis.
    Candia L; Marquez J; Gonzalez C; Santos AM; Londoño J; Valle R; Zabaleta J; Yaqub Z; Espinoza LR
    J Clin Rheumatol; 2006 Oct; 12(5):226-9. PubMed ID: 17023808
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combining traditional systemic and biologic therapies for psoriasis.
    Heffernan MP
    Semin Cutan Med Surg; 2010 Mar; 29(1):67-9. PubMed ID: 20430311
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Psoriasis--recent advances in understanding its pathogenesis and treatment.
    Krueger G; Ellis CN
    J Am Acad Dermatol; 2005 Jul; 53(1 Suppl 1):S94-100. PubMed ID: 15968269
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.